Viagra to Put 'Vision Loss' Reports on Label
Posted on: Monday, 4 July 2005, 09:00 CDT
THE makers of impotence drug Viagra may update its labels in the US to ref lect rare reports of vision loss.
The global pharmaceutical company Pfizer said it conducted a review of all reported incidences of "ocular events" after patients had taken Viagra.
It concluded that there was no evidence of increased risk of blindness. However, the company is still working with US federal regulators to update the drug's label to ref lect the vision loss reports.
Last month, the US Food and Drug Administration said it had 38 reports of blindness caused by a condition called NAION (non- arteritic anterior ischemic optic neuropathy) among users of Viagra.
While the FDA concluded no causal relationship between Viagra and NAION had been established, Pfizer has agreed to include on the label that these reports exist in order to inform physicians and patients.
Joseph Feczko, Pfizer's chief medical officer, said: "After more than 10 years of rigorous clinical study and worldwide safety monitoring of a medicine used by more than 27 million men, there is no evidence to suggest a link between Viagra and blindness or other serious ocular events."
Source: Herald, The; Glasgow (UK)
Related Articles
- Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), Which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
- NSCLC Drug Market to Exceed $4 Billion Between 2010 and 2015 According to the Report 'Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC'
- Doctors, Patients Urged to Report Adverse Drug Reactions
- Counting on the Viagra Brand in India Pfizer Set to Introduce Drug Next Week Despite a Crowd of Copies
- Despite Viagra's Cost, India Beckons Pfizer BUSINESS ASIA By Bloomberg
- Report: Rx Drug Sales to Soar in U.S.
- Amazon Biotech Announces a New Double-Blind Drug Trial Using AMZ 0026
- Pfizer: No Proof Viagra Causes Blindness
- Scientist Presses Case Against Pain Drugs ; Pfizer Disputes Research, but Stock Falls
- Report: Other Drugs May Raise Heart Risks
 |
 |
User Comments (0)
RSS Feeds